Summary
45 / 100 · Bulios Score
What speaks for it
- Revenue grew by 14% a year over the last 3 years.
- It passes 8 of the 9 points of the Piotroski financial health test.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 10% a year over the last 3 years.
- It missed profit estimates 7 times in the last 8 quarters.
- Out of every 100 GBP of revenue, only 1.5 GBP is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 32.2 GBP for 1 GBP of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (GBP)
Diluted EPS (GBP)
- Analyst estimate
Revenue grew by 14% a year over 5 years. Over the last 3 years it grew by 14% a year. For the next fiscal year analysts expect revenue to grow by 9.5%. Earnings per share fell by 10% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.03%
- Paid out of profit
- 33%
- Raised in a row
- 2 years
You receive $0.11 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 5
- Hold 1
- Sell 0
No analyst has published a price target.
83% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.